metoprolol + infliximab + etanercept + tocilizumab

This is a combination of four distinct pharmaceutical agents, each with different mechanisms of action and primary indications: - **Metoprolol** is a selective beta-1 adrenergic receptor blocker (beta-blocker) primarily used for cardiovascular conditions such as hypertension, angina, heart failure, and myocardial infarction. It reduces heart rate and cardiac output by antagonizing the effects of catecholamines at beta-1 receptors in the heart. Recent research also suggests metoprolol can inhibit IL-6 protein translation in monocytes, potentially reducing cytokine release syndrome (CRS)[8]. - **Infliximab** is a chimeric monoclonal antibody that binds to tumor necrosis factor alpha (TNF-alpha), inhibiting its pro-inflammatory activity. It is indicated for autoimmune diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. - **Etanercept** is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human TNF receptor linked to the Fc portion of human IgG1. It acts as a decoy receptor for TNF-alpha and TNF-beta (lymphotoxin alpha), thereby inhibiting their inflammatory effects. Etanercept is approved for rheumatoid arthritis and other inflammatory conditions[4]. - **Tocilizumab** is a recombinant humanized monoclonal antibody that targets both soluble and membrane-bound interleukin 6 (IL-6) receptors. By blocking IL-6 signaling pathways it reduces inflammation associated with autoimmune diseases such as rheumatoid arthritis, giant cell arteritis, systemic juvenile idiopathic arthritis (sJIA), polyarticular juvenile idiopathic arthritis (pJIA), cytokine release syndrome from CAR-T therapy or COVID-19[1]. There are rare case reports describing dual biologic therapy with etanercept plus tocilizumab in refractory cases; however there are no established clinical uses or approvals for combining all four agents together[5]. Such combinations would carry significant risk due to overlapping immunosuppressive effects.